JAZZ
Price
$170.48
Change
-$0.32 (-0.19%)
Updated
Dec 26 closing price
Capitalization
10.36B
65 days until earnings call
Intraday BUY SELL Signals
NUVL
Price
$104.09
Change
-$1.66 (-1.57%)
Updated
Dec 26 closing price
Capitalization
8.08B
66 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

JAZZ vs NUVL

Header iconJAZZ vs NUVL Comparison
Open Charts JAZZ vs NUVLBanner chart's image
Jazz Pharmaceuticals
Price$170.48
Change-$0.32 (-0.19%)
Volume$255.19K
Capitalization10.36B
Nuvalent
Price$104.09
Change-$1.66 (-1.57%)
Volume$205.56K
Capitalization8.08B
JAZZ vs NUVL Comparison Chart in %
JAZZ
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
JAZZ vs. NUVL commentary
Dec 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAZZ is a Buy and NUVL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 28, 2025
Stock price -- (JAZZ: $170.48 vs. NUVL: $104.10)
Brand notoriety: JAZZ and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAZZ: 22% vs. NUVL: 31%
Market capitalization -- JAZZ: $10.36B vs. NUVL: $8.08B
JAZZ [@Biotechnology] is valued at $10.36B. NUVL’s [@Biotechnology] market capitalization is $8.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAZZ’s FA Score shows that 0 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • JAZZ’s FA Score: 0 green, 5 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVL is a better buy in the long-term than JAZZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAZZ’s TA Score shows that 2 TA indicator(s) are bullish while NUVL’s TA Score has 4 bullish TA indicator(s).

  • JAZZ’s TA Score: 2 bullish, 4 bearish.
  • NUVL’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than JAZZ.

Price Growth

JAZZ (@Biotechnology) experienced а +2.09% price change this week, while NUVL (@Biotechnology) price change was +0.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

JAZZ is expected to report earnings on Mar 03, 2026.

NUVL is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JAZZ($10.4B) has a higher market cap than NUVL($8.08B). JAZZ YTD gains are higher at: 38.433 vs. NUVL (32.978). JAZZ has higher annual earnings (EBITDA): 183M vs. NUVL (-398.38M). JAZZ has more cash in the bank: 2.05B vs. NUVL (943M). JAZZ has higher revenues than NUVL: JAZZ (4.16B) vs NUVL (0).
JAZZNUVLJAZZ / NUVL
Capitalization10.4B8.08B129%
EBITDA183M-398.38M-46%
Gain YTD38.43332.978117%
P/E Ratio15.38N/A-
Revenue4.16B0-
Total Cash2.05B943M217%
Total Debt5.43BN/A-
FUNDAMENTALS RATINGS
JAZZ: Fundamental Ratings
JAZZ
OUTLOOK RATING
1..100
12
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
PROFIT vs RISK RATING
1..100
76
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
75
SEASONALITY SCORE
1..100
65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
JAZZNUVL
RSI
ODDS (%)
Bearish Trend 3 days ago
81%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
62%
Bearish Trend 3 days ago
74%
MACD
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
60%
Bearish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 7 days ago
60%
Bullish Trend 7 days ago
83%
Declines
ODDS (%)
Bearish Trend 20 days ago
58%
Bearish Trend 12 days ago
77%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
89%
Aroon
ODDS (%)
N/A
Bullish Trend 5 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
JAZZ
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RSPS29.240.05
+0.15%
Invesco S&P 500® Eql Wt Cnsm Stapl ETF
TEKY37.87N/A
N/A
Lazard Next Gen Technologies ETF
NXTE39.09-0.03
-0.06%
AXS Green Alpha ETF
ETHA22.14-0.03
-0.14%
iShares Ethereum Trust ETF
GGLL97.36-0.45
-0.46%
Direxion Daily GOOGL Bull 2X Shares

JAZZ and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with ZYME. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then ZYME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAZZ
1D Price
Change %
JAZZ100%
-0.19%
ZYME - JAZZ
44%
Loosely correlated
+0.04%
AMLX - JAZZ
43%
Loosely correlated
-1.28%
RPTX - JAZZ
38%
Loosely correlated
+0.78%
NUVL - JAZZ
38%
Loosely correlated
-1.57%
BMRN - JAZZ
37%
Loosely correlated
-0.35%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with RVMD. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
-1.57%
RVMD - NUVL
61%
Loosely correlated
-0.54%
XNCR - NUVL
60%
Loosely correlated
-1.49%
IDYA - NUVL
59%
Loosely correlated
-1.35%
VRDN - NUVL
58%
Loosely correlated
-1.24%
XENE - NUVL
56%
Loosely correlated
-0.38%
More